leisure time -WSS

leisure time

author：comprehensive 2025-09-06 02:04:25 - browse：288

Paul Biondi Flagship

Pharma giant Pfizer is turning to venture firm Flagship for new drug development, signing a deal worth up to $7 billion to mine new medicines from the latter’s portfolio companies.

Flagship and Pfizer announced Tuesday that they will each put $50 million into developing up to 10 drug candidates. Pfizer will have first rights to acquire each for up to $700 million, plus royalties. Flagship’s portfolio companies will also share in any payments that come out of the partnership.

Flagship has historically developed new medicines by forming and spinning out startup companies, some of which have signed their own collaboration deals with the likes of Amgen or Nestlé Health Science. But in recent years, the firm has been pursuing external partnerships through a new business division called Pioneering Medicines, led by former Bristol Myers Squibb executive Paul Biondi. Pioneering Medicines uses technologies and other scientific platforms being developed by Flagship’s portfolio companies to look for possible therapies in disease areas that the startup may not be working in.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Doudna institute plans to 'cure hundreds of diseases' with CRISPR

hotspot

WSS

New menopause drug shows promise in relief for hot flashes

Doulas covered by Medicaid under New York's new plan

FDA struggles to regulate food additives, sometimes for decades

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Generative AI mines health records to identify patients’ social needs

Solve the antibiotic resistance crisis with preventive drugs

focus

leisure time

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

Researchers explore possible ties between long Covid, menopause

Trump demands the U.S. pay no more for drugs than other countries … again

Studies point to risks of excluding people with obesity from drug trials

Bright Health sells Medicare Advantage business to Molina

NIH confirmation hearing shows politicization of research

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

STAT Summit: Michael J. Fox on progress in Parkinson's research

Continuity nursing helped my family in our darkest PICU moments

Hospital price transparency does save money, advocate argues

entertainment

Eli Lilly expects to double planned employment in Boston center

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

FDA gives detailed accounting of AI

The SUPPORT Act is critical to fighting the opioid crisis

The SUPPORT Act is critical to fighting the opioid crisis

NIH confirmation hearing shows politicization of research

leisure time

hotspot

focus

explore